The pharma giant said the second half will see a boost in performance
AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine has delivered sales of US$275mln in the first quarter as it made a bullish statement on its outlook.
The pharma giant expects a performance boost in the second half of 2021 as vaccine rollouts and lower infections will reduce the hit of the pandemic on trading.
Chief executive Pascal Soriot reiterated full-year guidance for the pharma giant after first-quarter figures were in line with expectations.
Total revenue for the year is estimated to jump 11-12%, with core earnings per share (EPS) coming in at US$4.75-5.